Fatherhood 2.0: The New Playbook By Ivanhoe Broadcast News on June 12, 2026

Orlando, Fla. (Ivanhoe Newswire) — Father’s Day is June 21st and this year, we are celebrating a new kind of dad. For years, the image of dad was pretty simple, the provider, the rule-maker, maybe even the punchline. But today’s father? He’s doing a lot more. Pew Research shows dads are spending more time with their kids than ever before. So, this Father’s Day, we’re looking at “dad 2.0” and the new playbook that’s changing families. https://www.ivanhoe.com/?p=37172&preview=1&_ppp=5cd44719da

Family Analog Summer: From Screen Time To Real Time By Ivanhoe Broadcast News on June 11, 2026

Orlando, Fla. (Ivanhoe Newswire) — More than half of Americans say they feel “addicted” to their phones. Kids and teens now average up to seven hours a day on entertainment screen time not including schoolwork. And for families, that time adds up. A recent study found parents spend more than five hours a day on their phones often during family time. So now, ask yourself a simple question: What if summer didn’t look like a screen? A growing number of families are trying something different, calling it an “analog summer.” https://www.ivanhoe.com/?p=37169&preview=1&_ppp=b90dc089f6

Gout: The Most Painful Arthritic Condition By Ivanhoe Broadcast News on June 10, 2026

ORLANDO, Fla. (Ivanhoe Newswire) — Gout is described as the most painful arthritic condition, and yet it’s nicknamed the “disease of kings.” That’s because it was historically understood as only caused by diet and lifestyle, and the food that caused it was only accessible to the very rich and royalty, therefore they had the highest rates of it. But anyone can get gout, and it’s a chronic condition that, if untreated, can permanently damage the body. Here’s more about the condition and misconceptions about it. https://www.ivanhoe.com/?p=37166&preview=1&_ppp=e91cf4209d

The Future of Pain Relief Without Risk of Addiction By Ivanhoe Broadcast News on June 9, 2026

RALEIGH, N.C. (Ivanhoe Newswire) — More than 50 million adults in the United States are living with chronic pain and for millions relief still comes with risks. The opioid crisis continues to claim tens of thousands of lives each year. Now, scientists are racing to find new ways to treat pain without addiction. Here’s more on the breakthroughs and the hope these new treatments could bring. https://www.ivanhoe.com/?p=37163&preview=1&_ppp=6096a71a9a

New Brain Secrets Uncovered By Ivanhoe Broadcast News on June 8, 2026

ORLANDO, Fla. (Ivanhoe Newswire) — The human brain has been described as one of the most complex structures in the known universe, containing 86 billion neurons, 85 billion other cells, and over 100 trillion connections. Being that complex, it’s no wonder that we have not fully mapped it yet. But there’s new research that is making the picture clearer than it has been. Ivanhoe has the details on what these discoveries are and how they can affect you. https://www.ivanhoe.com/family-health/new-brain-secrets-uncovered/

Primary Analysis of KYV-101 for the Treatment of Stiff Person Syndrome by Madaline Spencer| Published on: May 18, 2026

Primary Analysis of KYV-101 for the Treatment of Stiff Person Syndrome by Madaline Spencer| Published on: May 18, 2026 Naji Gehchan, MD, MBA, Chief Medical and Development Officer at Kyverna Therapeutics, discusses primary analysis of KYV-101 for the treatment of stiff person syndrome (SPS). https://checkrare.com/primary-analysis-of-kyv-101-for-the-treatment-of-stiff-person-syndrome/

Efficacy of Efgartigimod To Treat Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): ADHERE Trial by Madaline Spencer| Published on: May 20, 2026

Efficacy of Efgartigimod To Treat Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): ADHERE Trial by Madaline Spencer| Published on: May 20, 2026 Hans Katzberg, MD, Professor of Neurology at the University of Toronto and Neurologist at Toronto General Hospital, discusses post hoc analyses from the ADHERE clinical trial in chronic inflammatory demyelinating polyneuropathy (CIDP). https://checkrare.com/efficacy-of-efgartigimod-to-treat-patients-with-chronic-inflammatory-demyelinating-polyneuropathy-cidp-adhere-trial/